Target-specific immunoPET Imaging of Breast Cancer
Trial statusRecruiting
Trial phasePhase 1, Phase 2
Trial typeInterventional
Biological sexFemale
Age18-75
SponsorRenJi Hospital
About this trial
The aim of this study is to establish and optimize the Trop2/HER2-targeted PET/CT imaging method, and its physiological and pathological distribution characteristics, on the basis of which the diagnostic efficacy of the above imaging agents in breast cancer will be evaluated.
Eligibility criteria
Qualifiers
Aged 18-75 years old and of female gender；
Histologically confirmed diagnosis of breast cancer or suspected breast cancer by diagnostic imaging;
Capable of giving signed informed consent, including compliance with the requirements and restrictions listed in the informed consent form (ICF) and this protocol.
Disqualifiers
Pregnancy；
Severe hepatic and renal insufficiency;
History of serious surgery in the last month;
Allergic to antibody or single-domain antibody radiopharmaceuticals.
Trial design
Treatments tested in this trial
- [18F]F-RESCA-RT4
- [18F]F-RESCA-RB14
Treatment groups
200 Participants
are divided into 1 treatment groupLocations
1Renji Hospital, School of Medicine, Shanghai Jiao Tong University200127, ShanghaiShanghai Municipality, China
Sponsors and collaborators
RenJi Hospital
Lead sponsor
Source ClinicalTrials.gov